AstraZeneca Rebounds on Q3 Results as Shorts Sit Quiet

AstraZeneca has had one of its strongest weeks in months, jumping nearly 9% as Thursday's Q3 results gave bulls fresh ammunition. The question now is whether the rally has legs or whether the stock is simply closing the gap it lost over the prior quarter.

The share price tells the clearest story. AZN closed Thursday at 139.6p, up 6.96% on the day and 8.86% on the week, extending a 12.3% gain over the past month. The move came on the back of the Q3 earnings release on October 30, with the next event already pencilled in for February 9, 2027. That gives investors roughly 100 days to digest what the company put out this week.

The lending market offers no warning signal at all. Borrow availability is effectively unlimited: over 1.1 billion shares are available to lend, and the available-to-borrowed ratio reads above 9,999%, meaning the lending pool is nowhere near exhausted. Borrowing costs are nominal at around 0.71%, up slightly from mid-October lows but well within a range that has held for months. The ORTEX short score is 25.9, a low reading that places AZN in the 95th percentile for least-shorted stocks in the sector. There is no meaningful short thesis in the price right now, and the borrow market reflects that.

On the Street, recent analyst data is too stale to cite directly. The most relevant external signal is that AZN's ORTEX stock score has been running at 87.7, led by a growth pillar at 82.9 on the back of sharply rising forward EPS estimates. Factor scores paint a similar picture: the earnings yield rank is in the 81st percentile, the dividend score in the 89th, and the days-to-cover rank in the 75th. Valuation multiples have drifted higher with the price: the trailing PE is 15.5, up roughly 0.8 turns over the past month, and EV/EBITDA has moved up about 0.1 turn over the same period. Neither looks stretched for a large-cap pharma with a pipeline of this breadth. The softer signal is EPS surprise, which ranks only in the 40th percentile, suggesting the company has not been consistently clearing the bar set by analysts.

The most concrete piece of insider colour from the recent window is CEO Pascal Soriot's open-market purchase of 60,000 shares at 121.02p in mid-September, alongside a 2,500-share buy from Chairman Michel Demaré at roughly the same price. Both came before the Q3 rally, and both look well-timed in retrospect. On the institutional side, Wellington Management added 4.8 million shares as recently as August, and Capital Research and Management picked up a further 1.6 million by end-September. The ownership register is dominated by passive and near-passive holders: Handelsbanken Sverige Lm Index Fund holds 19.7% and BlackRock 8.9%, which means most of the flow on a week like this is structural rather than conviction-driven.

Closest peer GSK slipped 2.1% on the week while AZN climbed 8.9%, a divergence that stands out given their 68% price correlation. Eli Lilly gained 11.3%, the only peer to match AZN's pace, carried by its own strong results. The contrast with Haleon, down 16.2% on the week, illustrates how quickly the UK healthcare sector can reprice on a single print.

The setup heading into February centres on whether AZN can hold its new price level through the quieter months, and specifically whether the forward EPS revisions that drove the growth score higher prove durable as analysts update their models on the Q3 print.